Mar 07, 2023 / 07:50PM GMT
Andrew Harris Cooper - Raymond James & Associates, Inc., Research Division - Research Analyst
Welcome, everybody. Thanks for joining us at the Raymond James Institutional Investor Conference. I'm Andrew Cooper. I'm happy to be joined by Natera. We have CFO, Mike Brophy here, who's going to talk to us a little bit first about Natera in general, and then we're going to dive into some Q&A as well. So with that, I will just pass it straight to Mike.
Michael B. Brophy - Natera, Inc. - CFO
Great. Thanks, Andrew. I appreciate the time and being here today. So I'm on to do a couple of basic kind of intro slides here. So Natera is a leader in cell-free DNA technology. The first major product launch that we initiated was back in 2013, we launched our Panorama noninvasive prenatal diagnostic test, noninvasive prenatal test. That was a purpose-built test that utilizes a very flexible and sensitive PCR-based chemistry paired with a suite of algorithms that delivered really excellent performance in screening for fetal antipodes for NIPT. When we launched that product,
Natera Inc at Raymond James Institutional Investors Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers